MX2017008057A - Derivados de azabiciclooctano como agonistas de fxr para el uso en el tratamiento de enfermedades hepaticas y gastrointestinales. - Google Patents
Derivados de azabiciclooctano como agonistas de fxr para el uso en el tratamiento de enfermedades hepaticas y gastrointestinales.Info
- Publication number
- MX2017008057A MX2017008057A MX2017008057A MX2017008057A MX2017008057A MX 2017008057 A MX2017008057 A MX 2017008057A MX 2017008057 A MX2017008057 A MX 2017008057A MX 2017008057 A MX2017008057 A MX 2017008057A MX 2017008057 A MX2017008057 A MX 2017008057A
- Authority
- MX
- Mexico
- Prior art keywords
- liver
- gastrointestinal diseases
- treatment
- fxr agonists
- azabicyclooctane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Abstract
La invención proporciona métodos para la modulación de la actividad de receptores X farsenoide (FXR) usando compuestos de Fórmula (I) o (II). En particular, la invención proporciona el uso de compuestos de Fórmula (I) o (II), o un estereoisómero, enantiómero o sal farmacéuticamente aceptable de dichos compuestos, para el tratamiento o la prevención de enfermedades hepáticas y gastrointestinales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462093586P | 2014-12-18 | 2014-12-18 | |
PCT/IB2015/059450 WO2016097933A1 (en) | 2014-12-18 | 2015-12-08 | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017008057A true MX2017008057A (es) | 2017-09-28 |
Family
ID=54979887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017008057A MX2017008057A (es) | 2014-12-18 | 2015-12-08 | Derivados de azabiciclooctano como agonistas de fxr para el uso en el tratamiento de enfermedades hepaticas y gastrointestinales. |
Country Status (17)
Country | Link |
---|---|
US (2) | US20170368038A1 (es) |
EP (1) | EP3233083A1 (es) |
JP (1) | JP2017537960A (es) |
KR (1) | KR20170095965A (es) |
CN (1) | CN107106555A (es) |
AU (1) | AU2015365481B2 (es) |
BR (1) | BR112017011972A2 (es) |
CA (1) | CA2970866A1 (es) |
CL (1) | CL2017001566A1 (es) |
IL (1) | IL252596A0 (es) |
MX (1) | MX2017008057A (es) |
PH (1) | PH12017501046A1 (es) |
RU (1) | RU2017125365A (es) |
SG (1) | SG11201704340VA (es) |
TN (1) | TN2017000243A1 (es) |
TW (1) | TW201628615A (es) |
WO (1) | WO2016097933A1 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
PL3277286T3 (pl) | 2015-03-31 | 2021-11-08 | Enanta Pharmaceuticals, Inc. | Pochodne kwasu żółciowego jako agonisty fxr/tgr5 i sposoby ich stosowania |
US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
SG11201810600WA (en) | 2016-06-13 | 2018-12-28 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
WO2018039384A1 (en) * | 2016-08-23 | 2018-03-01 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators |
CN116854681A (zh) * | 2016-08-23 | 2023-10-10 | 阿德利克斯股份有限公司 | 用于治疗代谢病状和病症的激素受体调节剂 |
JOP20190040A1 (ar) * | 2016-09-14 | 2019-03-10 | Novartis Ag | توليفة من ناهضات fxr |
CA3039124A1 (en) | 2016-10-04 | 2018-04-12 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
AU2017339826A1 (en) * | 2016-10-05 | 2019-04-04 | Novartis Ag | Combination compositions comprising FXR agonists for treating or preventing a fibrotic,cirrhotic disease or disorder |
US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
CN110461328A (zh) | 2017-03-28 | 2019-11-15 | 吉利德科学公司 | 治疗肝疾病的治疗组合 |
CN110678450B (zh) | 2017-04-12 | 2023-06-20 | 日东制药株式会社 | 作为核受体激动剂的异噁唑衍生物及其用途 |
AU2018298253B2 (en) * | 2017-07-06 | 2020-11-19 | Xuanzhu Biopharmaceutical Co., Ltd. | FXR receptor agonist |
EP3681881B1 (en) | 2017-09-14 | 2022-11-02 | Ardelyx, Inc. | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders |
KR20200083528A (ko) | 2017-11-01 | 2020-07-08 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물 |
EP3704106B1 (en) | 2017-11-01 | 2023-04-12 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
WO2019089664A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Multicyclic compounds as farnesoid x receptor modulators |
EP3704113B1 (en) | 2017-11-01 | 2023-10-11 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid x receptor modulators |
CA3080893A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid x receptor modulators |
WO2019118571A1 (en) | 2017-12-12 | 2019-06-20 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
JP7243959B2 (ja) | 2017-12-22 | 2023-03-22 | シチュアン ケルン-バイオテック バイオファーマシューティカル カンパニー リミテッド | イソオキサゾール誘導体、その製造方法、及びその使用 |
CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
CN110357875B (zh) * | 2018-04-10 | 2022-06-21 | 浙江海正药业股份有限公司 | 氮杂双环辛烷类衍生物、其制备方法及其在医药上的用途 |
CN110357876B (zh) * | 2018-04-10 | 2022-06-28 | 浙江海正药业股份有限公司 | 氮杂双环辛烷类衍生物及其制备方法和用途 |
WO2020001304A1 (zh) * | 2018-06-26 | 2020-01-02 | 轩竹(海南)医药科技有限公司 | Fxr受体激动剂 |
CA3124702A1 (en) | 2019-01-15 | 2020-07-23 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
JP2022518603A (ja) * | 2019-01-31 | 2022-03-15 | 中国医▲薬▼研究▲開▼▲発▼中心有限公司 | 芳香環又は芳香族複素環化合物、その製造方法及び医薬使用 |
AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
CA3129949C (en) | 2019-02-19 | 2024-04-30 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
CN111825701B (zh) * | 2019-04-19 | 2023-12-08 | 正大天晴药业集团股份有限公司 | 含苯并噻唑的三环类fxr调节剂化合物 |
US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
MX2022000742A (es) | 2019-07-18 | 2022-02-14 | Enyo Pharma | Metodo para disminuir los efectos adversos del interferon. |
WO2021104021A1 (zh) * | 2019-11-29 | 2021-06-03 | 广东东阳光药业有限公司 | Tropifexor的新晶型及其制备方法 |
CN114728954B (zh) * | 2019-11-29 | 2023-10-17 | 广东东阳光药业股份有限公司 | Tropifexor的新晶型及其制备方法 |
CN114945361A (zh) | 2020-01-15 | 2022-08-26 | 法国国家卫生及研究医学协会 | Fxr激动剂在治疗丁型肝炎病毒感染中的用途 |
JP2023530645A (ja) * | 2020-06-09 | 2023-07-19 | バイキング・セラピューティクス・インコーポレイテッド | 肝障害を処置するための組成物及び方法 |
EP4277622A1 (en) | 2021-01-14 | 2023-11-22 | ENYO Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
CN113292555B (zh) * | 2021-04-28 | 2022-03-18 | 武汉纽瑞斯医药科技有限公司 | 一种Tropifexor的制备方法 |
TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Enyo製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
CN116987062A (zh) * | 2023-08-03 | 2023-11-03 | 中国热带农业科学院分析测试中心 | 一种氨基酸键联槟榔碱衍生物的制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007042465A2 (en) * | 2005-10-07 | 2007-04-19 | Novartis Ag | Combinati0n of nilotinib with farnesyl transferase inhibitors |
CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
US20130261108A1 (en) * | 2010-12-20 | 2013-10-03 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
EP2545964A1 (en) * | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
-
2015
- 2015-12-08 AU AU2015365481A patent/AU2015365481B2/en not_active Ceased
- 2015-12-08 EP EP15813923.8A patent/EP3233083A1/en not_active Withdrawn
- 2015-12-08 CA CA2970866A patent/CA2970866A1/en not_active Abandoned
- 2015-12-08 CN CN201580068503.5A patent/CN107106555A/zh active Pending
- 2015-12-08 BR BR112017011972A patent/BR112017011972A2/pt not_active Application Discontinuation
- 2015-12-08 KR KR1020177019415A patent/KR20170095965A/ko unknown
- 2015-12-08 RU RU2017125365A patent/RU2017125365A/ru not_active Application Discontinuation
- 2015-12-08 WO PCT/IB2015/059450 patent/WO2016097933A1/en active Application Filing
- 2015-12-08 SG SG11201704340VA patent/SG11201704340VA/en unknown
- 2015-12-08 US US15/534,324 patent/US20170368038A1/en not_active Abandoned
- 2015-12-08 TN TN2017000243A patent/TN2017000243A1/en unknown
- 2015-12-08 MX MX2017008057A patent/MX2017008057A/es unknown
- 2015-12-08 JP JP2017532168A patent/JP2017537960A/ja active Pending
- 2015-12-17 TW TW104142545A patent/TW201628615A/zh unknown
-
2017
- 2017-06-01 IL IL252596A patent/IL252596A0/en unknown
- 2017-06-06 PH PH12017501046A patent/PH12017501046A1/en unknown
- 2017-06-16 CL CL2017001566A patent/CL2017001566A1/es unknown
-
2018
- 2018-09-20 US US16/137,360 patent/US20190083473A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL252596A0 (en) | 2017-07-31 |
CA2970866A1 (en) | 2016-06-23 |
CN107106555A (zh) | 2017-08-29 |
US20170368038A1 (en) | 2017-12-28 |
US20190083473A1 (en) | 2019-03-21 |
PH12017501046A1 (en) | 2017-11-27 |
KR20170095965A (ko) | 2017-08-23 |
RU2017125365A (ru) | 2019-01-21 |
WO2016097933A1 (en) | 2016-06-23 |
TW201628615A (zh) | 2016-08-16 |
TN2017000243A1 (en) | 2018-10-19 |
AU2015365481B2 (en) | 2018-08-09 |
JP2017537960A (ja) | 2017-12-21 |
RU2017125365A3 (es) | 2019-07-17 |
EP3233083A1 (en) | 2017-10-25 |
CL2017001566A1 (es) | 2018-03-23 |
SG11201704340VA (en) | 2017-07-28 |
AU2015365481A1 (en) | 2017-06-22 |
BR112017011972A2 (pt) | 2017-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501046A1 (en) | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases | |
PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
PH12018501656A1 (en) | Methods for using fxr agonists | |
PH12017500941A1 (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
PH12016502179A1 (en) | Inhibitors of lysine specific demethylase-1 | |
MX2016016593A (es) | Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos. | |
EP4282479A3 (en) | Use of pridopidine to treat depression or anxiety | |
MY192717A (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
TW201613872A (en) | IRAK4 inhibiting agents | |
MX2017014192A (es) | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. | |
EA201790785A1 (ru) | Производные тетрагидроизохинолина | |
MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
MX2018004664A (es) | Antagonistas de ep4. | |
NZ729252A (en) | Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof | |
PH12016502352A1 (en) | Pharmaceutical composition | |
PH12016502353A1 (en) | Pharmaceutical composition | |
TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
MX2021005891A (es) | Sondas para la proyeccion de imagen de la proteina huntingtina. | |
MY186475A (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
EA201491227A1 (ru) | Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2 | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
EA201691796A1 (ru) | П-замещенные асимметричные мочевины и их применение в медицине | |
MX2020005557A (es) | Agonistas de fxr para el tratamiento de enfermedades hepaticas. |